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Abstract
The survival of oesophageal cancer is poor as most patients present with advanced disease. 
Radiological staging of oesophageal cancer is complex but is fundamental to clinical 
management. Accurate staging investigations are vitally important to guide treatment 
decisions and optimise patient outcomes. A combination of baseline computed tomography 
(CT), endoscopic ultrasound (EUS) and positron emission tomography (PET) are currently 
used for initial treatment decisions. The potential value of these imaging modalities to re-
stage disease, monitor response and alter treatment is currently being investigated. This 
review presents an essential update on the accuracy of oesophageal cancer staging 
investigations, their use in re-staging after neo-adjuvant therapy and introduces evolving 
imaging techniques, including novel biomarkers that have clinical potential in oesophageal 
cancer.
Keywords: Oesophageal cancer; TNM; staging; response; prognosis; computed tomography; 
endoscopic ultrasound; positron-emission tomography; magnetic resonance imaging
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Novel imaging techniques in staging oesophageal cancer
Radiological staging is vitally important in oesophageal cancer, serving to define the extent 
of disease. Accurate staging, along with clinical, pathological and physiological factors, 
assists clinicians with critical treatment decisions, provides information about a patient’s 
likely prognosis and can stratify patients into risk groups. [1]
Diagnosis and investigation
Oesophageal cancer is usually diagnosed in symptomatic patients following upper 
gastrointestinal endoscopy and biopsy. Occasionally, oesophageal tumours are initially 
diagnosed using computed tomography (CT) in patients suspected of having cancer, or less 
frequently as an incidental finding. Luminal contrast studies e.g. barium swallow are now 
rarely performed as a first line investigation, but are useful for assessing the degree of 
luminal stenosis and guiding oesophageal stent placement. (Fig. 1)
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Figure 1. Selected image from a double contrast barium swallow examination showing a stricturing 
mid oesophageal tumour with proximal retention of oral contrast.
Histology and tumour location
The two main histological cell types are adenocarcinoma and squamous cell carcinoma 
(SCC). Adenocarcinomas tend to involve the distal third of the oesophagus and the gastro-
oesophageal junction (GOJ). SCCs are usually located in the upper and middle thirds of the 
oesophagus. It is important to define the tumour location and confirm the histological cell 
type with biopsy because treatments differ accordingly. 
TNM staging classification
The globally recognised standard for staging oesophageal and GOJ tumours is the Union for 
International Cancer Control (UICC) Tumour Node Metastasis (TNM) classification, currently 
in its 8th edition. [2] (Table 1) 
Table 1. Tumour Node Metastasis (TNM) 8th edition of the oesophageal cancer staging 
classification
Primary tumour (T)
TX Primary tumour cannot be assessed
T0 No evidence of primary tumour
Tis Carcinoma in situ
T1 Tumour invades the lamina propria, muscularis mucosae, or 
submucosa
T1a Tumour invades the lamina propria or muscularis mucosae
T1b Tumour invades the submucosa
T2 Tumour invades muscularis propria
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T3 Tumour invades adventitia
T4 Tumour invades adjacent structures
T4a Tumour invades the pleura, pericardium, azygos vein, 
diaphragm or peritoneum
T4b Tumour invades other adjacent structures, such as the 
aorta, vertebral body or trachea
Regional lymph nodes (N)
NX Lymph node status cannot be assessed
N0 No regional lymph node metastases
N1 Metastasis in 1–2 regional lymph nodes
N2 Metastasis in 3–6 regional lymph nodes
N3 Metastasis in 7 or more regional lymph nodes
Distant metastases (M)
MX Presence of distant metastases cannot be assessed
M0 No distant metastases
M1 Distant metastases
One important difference between the 7th and 8th editions are the re-classification of stage 
sub-categories. The 7th edition stage IIIB and IIIC groups (T3-4a N1-3) are now re-classified as 
stage IVA, with M1 disease classified as stage IVB. These patients arguably have as poor an 
outcome as those with distant metastatic disease due to the substantial lymph node 
burden, which is known to be a major prognostic indicator. [3] Another change to the TNM 
8th edition is the separation of T1 tumours into T1a and T1b tumours. This differentiation is 
important because the risk of lymph node metastases increases from 3-6% for T1a mucosal 
tumours, to 21-24% for T1b submucosal tumours. [4] This differentiation of T1 tumours is 
important for guiding endoscopic versus surgical management decisions.
Oesophageal Cancer Staging Pathway
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Initial staging with contrast-enhanced CT of the thorax and abdomen +/- pelvis should be 
performed to define irresectable disease or identify distant metastases that preclude radical 
therapy. [5] The pelvis should be included in the CT protocol if the primary tumour extends 
beneath the diaphragm. If the patient is thought to have potentially curable disease, with 
either surgical or oncological management, then positron emission tomography (PET) 
combined with CT (PET/CT) is recommended, followed by endoscopic ultrasound (EUS). 
Diagnostic laparoscopy should also be performed in patients with a tumour involving the 
stomach. The recently published National Institute for Health and Care Excellence (NICE) 
guidelines recommends PET/CT for all patients with potentially curable disease (except in 
patients with T1a tumours) and to only offer EUS in cases where it may change 
management. [1] 
The optimal order of staging investigations is debatable, although it is generally agreed that 
PET/CT should be performed before EUS. Distant incurable disease detected on PET/CT 
would prevent a patient from undergoing a potentially risky and unnecessary endoscopic 
procedure. One study attempted to calculate the most favourable staging strategy using 
data from 216 consecutive patients. [6] Using likelihood ratios for 4 different staging 
combinations, the optimal staging strategy was found to be an initial PET/CT, with CT and 
EUS adding little additional information afterwards. However, the cost-effectiveness of such 
a strategy must be considered. [7]
The role of EUS is more controversial. A large single-centre study investigated the value of 
EUS in the staging pathway and concluded that its benefit in tumours staged T2-T4a was 
minimal compared to potential complications. [8] In contrast, EUS has been found to impact 
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on treatment decisions in 29% of patients, mainly when diagnosing lymph node metastases 
and when defining the gross tumour volume (GTV) during radiotherapy planning. [9] PET 
tumour and disease length measurements have been shown to significantly differ, with PET 
tending to yield shorter dimensions. [10] Furthermore, the rate of edge of radiotherapy field 
relapses are low when EUS measurements are included in GTV planning. [11] Further 
research evaluating the optimal staging strategy with EUS is required.
Staging Techniques
CT should be performed with intravenous contrast, where appropriate. (Fig.2) The 
conspicuity of the primary tumour, lymph node involvement and distant metastases is 
improved. 
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Figure 2. Selected axial and sagittal CT images of a patient with an obstructing distal oesophageal 
adenocarcinoma (white arrow), staged T3 N2 M0. Residual fluid caused by the luminal narrowing 
can be seen proximally.
PET/CT is routinely used in oesophageal cancer staging pathways worldwide. Strict patient 
preparation should be adhered to.  Patients should be nil-by-mouth for 4-6 hours before 
scanning and their serum glucose level tested prior to radioisotope injection. [12] All 
patients should rest before imaging because increased activity in skeletal muscles can 
increase muscle radioisotope tracer uptake. If the serum glucose level is more than 7 
mmol/L, fluorodeoxyglucose (FDG) uptake in the primary tumour and metastases can be 
impaired. In addition, metformin can cause increase bowel uptake. [13]
EUS is considered the ‘gold standard’ imaging technique for assessment of loco-regional 
stage but is operator dependent. EUS is not without risk; there are potential complications 
associated with sedation, the risk of oesophageal perforation and failure to cross stenotic 
tumours. A generally reported failure to cross rate is approximately 30% but figures as low 
as 3% using a slim endoscope have been reported. [14]
Few centres use magnetic resonance imaging (MRI) routinely as a staging investigation and 
most MRI data in the literature were obtained in a research setting. MRI is technically 
difficult because the images are prone to movement artefact from the heart, lungs and 
diaphragm. [15] MRI is potentially valuable when a tumour is impassable with EUS. Results 
of pathological validation studies have shown promise. [16-18]
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T-stage
T-stage classifies the depth of tumour invasion by anatomical landmarks and is an important 
predictor of survival. Five-year overall survival rates approach 82% when the tumour is 
limited to the mucosa or submucosa. [19] As described above, the depth of tumour invasion 
is associated with increasing risk of lymph node metastases. Approximately 74% of pT3 
tumours and 83% of pT4 tumours have regional lymph node metastases. [20]
An interesting phenomenon that occurs in patients with a tumour situated in a segment of 
Barrett’s oesophagus is duplication of the muscularis mucosae. This has potentially 
significant implications when staging early superficial tumours and should be considered. 
[21] 
EUS is the most accurate imaging modality for T-staging, with studies finding the accuracy to 
be more than 80%. [22, 23] Due to its superior contrast resolution, the individual layers of 
the oesophageal wall are well visualised compared to CT and PET. In addition, EUS benefits 
from ‘real-time’ imaging to assess for adherence to adjacent structures such as the aorta. 
(Fig. 3) Encasement of the aorta of more than 180 degrees indicates a highly likelihood of 
aortic invasion, with more than 270 degrees of encasement almost inevitable for 
involvement. [24]
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Figure 3. A selected EUS image of an oesophageal tumour with an adjacent lymph node metastasis 
(white calipers). The inner hypoechoic oesophageal layer (long white arrow) represents the 
muscularis mucosa, the thin middle hyperechoic layer (black arrow) represents the submucosa and 
the outer hypoechoic layer (short black arrow) represents the muscularis propria. This tumour was 
staged T3 because there was invasion through the muscularis propria to the adventitia.
Circumferential involvement of the oesophagus on CT is suggestive of at least T3 disease. 
[25] One advantage of CT is the determination of tumour resectability.  Identification of fat 
planes between the tumour and adjacent structures suggests an absence of direct invasion. 
However, fat planes can be difficult to assess if the tumour abuts an adjacent structure, or 
when imaged following radiation treatment. The sensitivity and specificity of CT for 
assessment of resectability is up to 100% and 80%, respectively. [26] MRI has been reported 
to have similar accuracy. [27]
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EUS provides excellent contrast resolution and is useful for distinguishing early T1 tumours 
from more advanced disease, with sensitivity and specificity of 81.6% and 99.4%, 
respectively. [22] The sensitivity and specificity of EUS for T1a tumours is 85% & 87% and 
86% & 86% for T1b tumours, respectively. [28] 
PET is unlikely to add additional information regarding T-stage. The inherent poor spatial 
resolution of PET, approximately 5 mm, limits accurate determination of tumour depth. [29] 
However, an advantage of PET is the quantification of metabolic tumour activity. (Figure 4) 
Adenocarcinoma and SCC both have a high affinity for FDG, although adenocarcinomas that 
have high mucinous content, that are poorly differentiated, or have signet-ring subtype can 
have poor FDG uptake. SCCs tend to have higher FDG uptake than adenocarcinomas. [30] 
The maximum standardised uptake value (SUVmax) has been shown to have prognostic 
significance, although significant results are not always reproduced. [31]
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Figure 4. An example of FDG-uptake within a distal oesophageal tumour. The maximum standardised 
uptake value (SUVmax) can be quantified and is commonly reported in oesophageal cancer staging. 
Uptake within the myocardium is commonly seen because of cardiac activity.
Tumour length is an important prognostic factor and has been shown to be independently 
associated with survival. [32] Pathological correlation of tumour length is challenging 
because ex-vivo tumours can shrink by up to one third if not fixed and prepared adequately. 
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[33] Measurement of tumour and disease length on imaging is important, guiding 
radiotherapy and surgical decisions, particularly the operation choice based on the location 
of the predicted proximal and distal margins. Circumferential resection margin involvement 
(CRM) is now generally considered important for prognosis. [34] Advanced T-stage is 
independently associated with CRM involvement, with a more than 25-fold increase in 
likelihood once the tumour is staged T3 or greater. [35]
N-stage
The TNM classification defines regional lymph nodes as those draining the oesophagus, 
irrespective of the site of the primary tumour. [36] Coeliac axis and para-oesophageal nodes 
in the neck are included, but not supra-clavicular lymph nodes. The presence of lymph node 
metastases is a major prognostic indicator and many studies have shown their significance. 
[37-40] Patients without lymph node metastases have an overall 5-year survival rate of 70-
92% when treated by surgical resection, but this falls to 18-47% if metastases are 
pathologically confirmed. [3]
There are extensive data available on the accuracy of lymph node staging. In general, all 
staging investigations tend to ‘under-stage’ lymph node metastases due to their respective 
limitations. [41] One meta-analysis found the sensitivity of CT, EUS and PET/CT for the 
detection of regional lymph node metastases was 50%, 80% and 57%, respectively. [7] The 
specificity was 83%, 70% and 85%, respectively. These figures show that EUS is more 
sensitive than CT and PET, therefore correctly excluding more regional lymph node 
metastases. 
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CT relies on anatomical information only and has relatively poor accuracy, with sensitivity as 
low as 18%. [42] One reason is that CT cannot differentiate between benign and normal 
sized lymph node metastases. EUS is considered the gold-standard investigation for N-
staging. EUS is more sensitive than PET (81% vs 33%) but less specific (67% vs 89%). [43] EUS 
provides the opportunity for fine needle aspiration (FNA), allowing histological confirmation 
which improves the sensitivity up to 95%. [22] EUS-FNA of high peri-oesophageal and 
coeliac axis nodes can also be performed as a ‘problem-solver’, which adds valuable 
information when clinicians are deciding whether the patient is suitable for radical therapy.
PET provides descriptive metabolic information about the lymph nodes, however the main 
limitation of PET is the poor spatial resolution. [44] Detecting small lymph node metastases 
and differentiating peri-tumoural nodes from the primary tumour can be challenging.  A 
meta-analysis of 12 studies including 490 patients reported an overall sensitivity of 51% and 
specificity of 84% for PET N-staging. [45] A more recent meta-analysis demonstrated that 
the pooled sensitivity and specificity of PET/CT was 55% and 76%, respectively. [46]
One study measured the size of the resected lymph nodes and their metastases in patients 
radiologically staged cN0. The sensitivity of CT, EUS and PET was 39.7%, 42.6% and 35.3%, 
respectively and the specificity was 77.3%, 75.0% and 90.9%, respectively. [41] The main 
reason for such poor sensitivity was that 82% of lymph node metastases measured less than 
6 mm and 44% less than 2 mm (classed as micro-metastases), which cannot be visualised on 
current imaging modalities. Further research is required to improve detection of lymph 
node metastases in patients with oesophageal cancer. 
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M-stage
The likelihood of distant metastases increases with advanced T- and N-stage. If unequivocal 
distant metastatic disease is detected on cross-sectional imaging, the patient receives 
palliative therapy unless specific oligo-metastatic disease can be resected. The common 
sites for distant metastatic disease are non-regional lymph nodes, liver, lung and bone. 
(Figure 5) 
Figure 5. An example of the added value of PET/CT in the oesophageal cancer staging. No focal 
lesions were visible on CT (top left). The patient was deemed suitable for radical therapy therefore a 
PET/CT was performed. This showed a mildly FDG-avid focus in segment 4a of the liver (top right and 
bottom middle red circles). This lesion was confirmed as a metastasis on MRI diffusion weighted 
imaging (bottom left).
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The major advancement from the introduction of PET/CT into the oesophageal cancer 
staging pathway is the superior detection of distant metastases not identified by CT. PET/CT 
can change management decisions in up to 38% of patients. [47] PET/CT has a greater 
sensitivity for distant metastases than CT (71% versus 52%, respectively). Specificity for 
distant metastases is similar (93% versus 91%). [7] It is vitally important to detect distant 
metastatic disease to prevent patients undergoing major intervention when the chances of 
survival are poor. Quality of life must be considered because surgical patients that die 
within 2 years of oesophagectomy never fully regain their quality of life. [48] 
Re-staging Oesophageal Cancer
The practice of re-staging is much more varied between institutions with few guidelines 
available to inform practice. Re-staging with CT and PET/CT is commonplace in the USA, but 
more restricted in the UK due to the financial constraints of the NHS. Evidence for re-staging 
with each modality differs but generally the accuracy of repeat investigation and response 
evaluation is suboptimal. [49] The main questions that re-staging aims to answer are 
whether the disease is still curable (i.e. to exclude disease progression), how much disease 
remains (i.e. assessing response) or whether a complete response (confirmed 
pathologically) has occurred. Re-staging can also be used to assess response during therapy 
and subsequently guide it, however there is evidence to suggest accuracy rates are 
suboptimal.
Evaluation of Response
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Whilst response rates to neoadjuvant chemotherapy and chemoradiotherapy vary 
considerably, a substantial number of patients do not exhibit a meaningful pathological 
response (indeed, the majority of patients receiving neo-adjuvant chemotherapy). [50] 
These patients presumably have chemo- or radio-resistant tumours, resulting in a real risk 
that they develop local or systemic progression during therapy. The gold standard 
assessment of response is pathological tumour regression grade (TRG), e.g. the Mandard 
Grade [51], which stratifies patients from complete response (TRG1) to no response (TRG5).
Such disease progression is critical to identify because any attempted surgery will likely be 
futile, either resulting in an abandoned procedure (due to technical risks during trial 
dissection), or early ‘recurrence’ following ostensibly successful resection. This risk has been 
gradually recognised; in the first generation of neo-adjuvant chemotherapy trials such as 
the MRC OEO2 trial [52], there were minimal stipulations for staging, and none for re-
staging. As a result, these trials may have underestimated the survival benefits of neo-
adjuvant therapy, as they logically must have included patients with incurable disease who 
still underwent resection. In the OEO5 trial [53], disease progression was demonstrated by 
CT on an intention to treat basis in 5% of patients before surgery, whilst in a further 5% 
surgery was abandoned due to unsuspected disease progression. In the CROSS trial [54], 4% 
of patients randomised to neo-adjuvant chemo-radiotherapy demonstrated disease-
progression before surgery, with a further 4% suffering an abandoned resection. These 
results demonstrate that at least 10% of patients have disease progression following 
therapy but more importantly that current imaging strategies are just 50% sensitive for this.
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The prediction and monitoring of early treatment response using PET/CT is currently of 
great interest. The MUNICON-1 trial investigated PET uptake pre- and post- neo-adjuvant 
chemotherapy and found that an SUVmax reduction of 35% after 2 weeks predicted response 
at the end of the 12-week cycle. [55] The trial showed that discontinuation of chemotherapy 
in metabolic non-responders did not affect their prognosis and prevented further exposure 
to potential side-effects of treatment. The MUNICON-2 trial investigated the utility of PET-
guided management, adding radiotherapy to conventional neo-adjuvant chemotherapy in 
non-responders. [56] PET responders had longer 2-year survival than non-responders (71% 
vs 42%) but this difference did not reach statistical significance (p=0.10).
Imaging Modalities in Re-staging
As with staging, all three aspects of the TNM classification can be assessed, although these 
are confounded by the local effects of chemo/radiotherapy. In addition, locally resectable 
re-staging of N-stage has little effect on operative strategy.
CT is usually performed after neo-adjuvant therapy, traditionally being used to exclude 
disease progression prior to surgery, rather than assessing response. This is typically done 
by semi-quantitatively comparing disease volumes using response criteria such as the 
Response Evaluation Criteria in Solid Tumours (RECIST). [57] However, data suggests that 
this tool has poor discrimination for classifying response. [58] The use of CT in response 
assessment is relatively poor, with sensitivity and specificity ranging between 33% and 55%, 
and 50% and 71%, respectively. [59] Whilst not able to precisely stratify response at a 
microscopic level, CT may provide useful surrogate prognostic information, by identifying 
down-staging (a reduction in tumour T- and N-stage). A large study demonstrated that 
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down-staging on re-staging investigations provides useful prognostic information. This study 
found that patients with down-staged tumours after neo-adjuvant chemotherapy 
experienced improved survival compared with patients without a response (p<0.001), and 
such down-staging was the strongest independent predictor of survival after adjusting for 
patient age, tumour grade, pre-treatment stage, lymphovascular invasion, resection margin 
status and surgical resection type (hazard ratio 0.43; 95% confidence intervals 0.31-
0.59). [60]
Although EUS performs well in the initial staging of oesophageal cancer, its value in re-
staging oesophageal cancer is doubtful. The accuracy of post neo-adjuvant EUS is relatively 
poor (59% for both T-stage and N-stage). EUS does not accurately detect down-staging of 
the tumour, even when a complete pathological response is achieved. [61] Likely reasons 
for the inaccuracy may be post-treatment inflammation and fibrosis, which distort the 
architecture of the oesophageal wall, resulting in over-estimation of T-stage even following 
substantial tumour regression. Accuracy is relatively preserved in patients with minimal 
response, whilst almost entirely lost in patients with a substantial local response, in whom 
fibrosis may be indistinguishable from residual tumour. [62, 63]
Early evidence for MRI, particularly diffusion weighted imaging (DWI) in restaging and 
treatment response evaluation is promising, although more validation must be performed. 
Clinical responders have been associated higher apparent diffusion coefficient (ADC) values 
than non-responders and lower baseline ADC values have been associated with poorer 
response to chemo-radiotherapy and survival. [64] However, a similar study found an 
opposing effect, with pathological responders associated with lower baseline ADC values 
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and increasing ADC values after neo-adjuvant therapy compared to non-responders. [65] 
Further research investigating MRI in oesophageal cancer staging, re-staging and treatment 
planning is required.
PET/CT Response
The combination of functional and cross-sectional imaging provided by PET/CT has been 
shown to outperform CT alone. [66] Analogous to RECIST, Positron Emission Tomography 
Response Criteria in Solid Tumours (PERCIST) uses reduction or progression in tumour 
avidity to stratify response into complete and partial metabolic response, and stable and 
progressive metabolic disease. [67] However, sensitivity and specificity for metabolic 
response is approximately 70%, and hence has yet to show clinical utility. [68] Furthermore, 
PET/CT is unable to reliably exclude or identify pCR following either neo-adjuvant 
chemoradiotherapy [66] or chemotherapy. [69]  Although not necessarily reliable for 
individual patients, the majority of patients classified as Mandard TRG 1-3 demonstrate a 
metabolic response. [70] 
Typically, response assessment focusses on the primary tumour. Metabolic response of 
presumed nodal metastases can also be assessed. Whilst this is usually concordant with the 
primary tumour, a disparity has been shown in approximately 5% of patients. [69] In 
addition, a metabolic nodal response (mNR) has been shown to be a positive prognostic 
marker, independent of established pathological markers and metabolic response of the 
primary tumour. [71] It is hypothesised that metabolic tumour response is a surrogate of 
pathological tumour response (TRG) and mNR a surrogate of the recently described concept 
of pathological nodal response [72], although these concepts require validation. Several 
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caveats apply to metabolic response of the primary tumour. Determining whether residual 
avidity is due to tumour necrosis with resultant inflammation, or metabolically active 
residual tumour is subjective and challenging.
Limitations in response assessment mean that imaging modalities are insufficient for 
identifying or excluding residual disease in isolation. As a result, studies combining 
modalities have been attempted, with varying success. One study found little additional 
benefit of resection when complete response was evident on PET/CT. [73] These data 
complement the ‘watch-and-wait’ approach currently being trialled in rectal cancer. [74] 
Conversely, a combination of EUS and PET/CT following neo-adjuvant chemoradiotherapy 
was investigated, but was insufficient to accurately select patients for non-operative 
management. [75] The recent Dutch preSANO study assessed patients following neo-
adjuvant chemoradiotherapy with endoscopy, biopsies and EUS. [76] Patients with 
demonstrable residual disease proceeded to surgery, whilst those with possible pCR were 
assessed with PET/CT. Significant false negative rates (i.e. missing residual disease) were 
seen, approximately 10% for EUS and endoscopic biopsies and a further 15% for those 
undergoing PET/CT. This assessment regimen is currently being assessed in the randomised 
3 SANO trial.
Insight into evolving imaging techniques
There are several evolving imaging techniques that, if validated, may improve staging 
accuracy in oesophageal cancer, enhance the prediction of prognosis, assist in re-staging 
disease and improve patient outcomes.
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MRI
Higher strength MRI scanners have demonstrated excellent T-staging accuracy in studies 
comparing imaging characteristics with ex-vivo specimens. The accuracy of a 4.7 Tesla MRI 
scanner was 94% and replicated with high resolution 1.5 Tesla MRI. [77, 78] One hundred 
percent accuracy has been reported using a 7 Tesla MRI scanner when compared to 
oesophageal resection specimens [79] but further in-vivo validation is required. If replicated 
in vivo, MRI may also assist with prediction of CRM involvement, which would be a valuable 
decision aid when planning the appropriateness and approach of surgery. Whilst whole-
body MRI is being trialled in lung and colorectal cancer [80], only pilot data currently exists 
in oesophageal cancer. [81] 
Radiomics
Radiomics is a current area of great interest. This post-processing technique aims to extract 
large amounts of additional quantitative data from a selected region of interest within an 
image. [82, 83] These data quantify underlying tumour characteristics by examining the 
frequency and spatial distribution of individual voxel values. Radiomics can be used to 
analyse Hounsfield units on CT, signal intensities on MRI and uptake values on PET. 
Heterogeneity of values within a tumour are thought to reflect variations in angiogenesis, 
vascularity, hypoxia and necrosis. [84]
Radiomics have been investigated in oesophageal cancer. [85] There have been increasing 
numbers of significant associations between radiomic parameters/signatures and TNM 
stage, treatment response and survival found. [31, 86, 87] However, many of these studies 
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include small sample sizes and are likely to report false-positive results. [88] One large, 
single centre study developed and internally validated a prognostic model including PET 
radiomics and found that model performance for overall survival improved compared to 
traditional clinical factors. [89] One critical aspect and potential limitation of radiomics is the 
reliability and reproducibility of these features. Much radiomics research is now 
concentrating on defining stable features for future application. [90]
Artificial Intelligence
Lastly, the application of artificial intelligence techniques in oesophageal cancer is a natural 
progression of current imaging research. Such applications could include the rapid, 
automatic detection of a tumour on imaging, the ability to delineate the primary tumour 
and lymph nodes, disease monitoring during treatment and prediction of response to 
treatment. The use of deep learning techniques such as convolutional neural networks to 
predict response to neo-adjuvant chemotherapy have been investigated for PET imaging. 
[91] There may also be a role for artificial intelligence in treatment planning. 
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Summary
In conclusion, this review presents the latest evidence in oesophageal cancer staging, re-
staging, response evaluation and novel evolving imaging techniques. Oesophageal cancer 
staging is complex and treatment decisions are multi-factorial. Accurate staging 
investigations are vital for management decisions, however, data presented highlight 
deficiencies, particularly in lymph node staging. In addition, the optimal staging pathway has 
not yet been agreed. The process of re-staging surgical candidates prior to surgery needs to 
be standardised and more robust markers of response identified. PET/CT has shown great 
promise in quantifying treatment response, including early treatment re-assessment, but 
multi-centre validation studies are lacking. Future oesophageal cancer imaging research 
should address these areas, aiming to improve staging accuracy, and provide clinicians with 
a clear evaluation of treatment response or progression. The role of hybrid imaging in 
treatment planning must also be investigated further. Improved imaging may lead to 
optimised clinical treatment decisions, which in turn may contribute towards significant 
advances in the outcomes of patient with oesophageal cancer.
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Practice Points
 Most patients with oesophageal cancer present with advanced disease
 The risk of lymph node metastases increases with advanced T-stage
 PET/CT should be performed before EUS during initial staging
 PET/CT has a greater sensitivity for distant metastases than CT alone and changes 
management in a substantial proportion
 CT should be performed after neo-adjuvant therapy to exclude progression prior to 
surgery
Research Agenda
 The optimal oesophageal cancer staging strategy needs to be defined
 Accurate detection of lymph node metastases must be improved
 Improved assessment of treatment response with CT and PET is needed
 The role of imaging to evaluate early response is required
 The role of MRI in staging, response evaluation and treatment planning should be 
investigated
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